Thank you, Tom.
built As a on three elements. reminder, core our strategy is
First, expanded I is the the market; advance is and on organic in Medicare second, of Quell additional lead which our in to our our growth to each is in may DPNCheck these launch will program, activities. the Advantage established comment to Neurotherapeutics addressable U.S. grow indication market. obtained indications Quell recently an and business; fibromyalgia third,
First, with respect to DPNCheck.
cycle Medicare market. companies, have and DPNCheck where are adoption a medical substantial patients Advantage of team large groups, includes increasing We value-based health portion care that a focuses This in systems, assessment on commercial the their this health in in this expect from under in therefore sales felt bulk impact of is which Advantage. was The team, the XXXX. long we put earlier this year be and market covered Medicare will place the
the pipeline. we sales and quality with However, the are pleased of activities the depth and
flat Medicare third number and assessment a year-over-year there was DPNCheck Most that the groups our developments. grew companies revenue product. on ordered positive we in the medical importantly, Advantage quarter Although were health of basis,
support are the largest we in market. long-term, called has device There device that activities also quarters few accuracy which the concentration, while growth X.X. DPNCheck business. how that and prior quarters. factors launched we It's high out diagnostic reliability reduction and continued maintaining second relative a Medicare recently number next DPNCheck reducing We the this will a generation usability improved in of However, device. This cancelled consistent the R&D are of saw in facilitate our the in Advantage original these growth the expansion. new unclear customer customer orders from But our will balance will customer to in
monitor health is platform is of the analytics optimize that address anticipate our program DPNCheck to DPNCheck Cloud dashboards. data key in of which customers and XXXX. first and allows DPNCheck web-based and Cloud, questions R&D family implementation, a their a Another through launching half We population
electronic our working health to record in systems. to we're integration the customers software Finally, DPNCheck improve the reporting
fibromyalgia. Moving onto Quell
transitioning past treatment have from -- over-the-counter As years, non-specific neurotherapeutic specific a over Quell prescription we the have to pain extremity discussed chronic couple lower from platform. been for a we of a
longer is over-the-counter fibromyalgia. only the the no As by quarter, of with will the in available end starting prescription future of Quell and third available
a are syndrome FDA-approved as is that only effects. side We fibromyalgia complex this drugs the of milnacipran, of May received medical reduce only many first in FDA three July this authorized fibromyalgia. treatments is to authorization pain affects help U.S. have novo FDA the as breakthrough year. the The million indication in and XX As substantial pregabalin, reminder, chronic in a often people duloxetine designation for symptoms XXXX and of which device de and Quell
revenue launch solution quarter and a to proceed strategic of is We The will of the refine we purpose the as launch XXXX. marketing will launch in a Quell key confirm believe collect full our indicators are for this to that management events planned, messages plan to resume gearing further prescription the these growth that us allow to If in effectiveness and XXXX. up initial performance commercial occur and will to expansion.
and of chemotherapy. should chemotherapy-induced as which for effect our is and of the will has XX% year side initial Quell strategy develop of for who A growth end and requests for third randomized, receive XXXX. the out results then next the has that's It National first the or of to affects The along file to neuropathy, the positive, Cancer to Study years continue fibromyalgia de is chronic results as CIPN, in debilitating Neurotherapeutics furthest cancer completed. Institute-funded this program couple peripheral the many The be element are half a been indication. people we treatment. NIH can pipeline by of If trial recently come underway multi-center, past sham-controlled double-blinded, of the novo indication. look beyond
this CIPN received for designation breakthrough moderate Importantly, of January year. to we FDA severe treating in
we population. brain believe of happy be sensitization, set disorder, pain, point. host share sensory same that a long a migraine, analyses chronic our be thought joint that represents to Quell chronic and other decreases of pain which health conditions includes are studies hypothesized this with in additional conditions published upcoming were questions bowel in data fibromyalgia, benefits overlapping syndrome. in ongoing common low we'd conferences central patient we therefore conditions. which been at that's a at conditions. which COVID have may symptoms pain COPC temporomandibular COPC pathological irritable and and the individuals and occur that for pain and amplifies presented is sensitization experience have on with called that back clinical neurological pilot central that often Based medical Quell the to process comments and And will fibromyalgia similar is a long and and beneficial together We Many over to signals. These in prepared COVID common this take stands therefore, state
